These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28929515)

  • 1. Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.
    Origa R; Ponti ML; Filosa A; Galeota Lanza A; Piga A; Saracco GM; Pinto V; Picciotto A; Rigano P; Madonia S; Rosso R; D'Ascola D; Cappellini MD; D'Ambrosio R; Tartaglione I; De Franceschi L; Gianesin B; Di Marco V; Forni GL;
    Am J Hematol; 2017 Dec; 92(12):1349-1355. PubMed ID: 28929515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major.
    Ponti ML; Comitini F; Murgia D; Ganga R; Canu R; Dessì C; Foschini ML; Leoni G; Morittu M; Perra M; Pilia MP; Casini MR; Zappu A; Origa R
    Dig Liver Dis; 2019 Apr; 51(4):561-567. PubMed ID: 30658940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
    Ferreira J; Bicho M; Serejo F
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
    Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
    Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
    J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the treatment of chronic hepatitis C virus infection in cirrhosis.
    Vezali E; Aghemo A; Colombo M
    Clin Ther; 2010 Dec; 32(13):2117-38. PubMed ID: 21316532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
    Lanini S; Scognamiglio P; Mecozzi A; Lombardozzi L; Vullo V; Angelico M; Gasbarrini A; Taliani G; Attili AF; Perno CF; De Santis A; Puro V; Cerqua F; D'Offizi G; Pellicelli A; Armignacco O; Mennini FS; Siciliano M; Girardi E; Panella V; Ippolito G;
    BMC Infect Dis; 2018 May; 18(1):223. PubMed ID: 29769038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatitis C virus infection in thalassemia.
    Butensky E; Pakbaz Z; Foote D; Walters MC; Vichinsky EP; Harmatz P
    Ann N Y Acad Sci; 2005; 1054():290-9. PubMed ID: 16339677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response.
    García-Ros A; Morán S; Núñez V; García-Ros G; Ruiz G; García-Solano J
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109770
    [No Abstract]   [Full Text] [Related]  

  • 12. Why is viral eradication so important in patients with HCV-related cirrhosis?
    Velosa J
    Antivir Ther; 2017; 22(1):1-12. PubMed ID: 27553973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
    Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting.
    Chirino-Sprung RA; Dehesa M; Wolpert E; Corona-Lau C; García-Juarez I; Sánchez-Ávila JF; Moctezuma-Velázquez C; Kershenobich D
    Rev Invest Clin; 2016; 68(4):203-12. PubMed ID: 27623039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort).
    Gentile I; Scotto R; Coppola C; Staiano L; Amoruso DC; De Simone T; Portunato F; De Pascalis S; Martini S; Macera M; Viceconte G; Tosone G; Buonomo AR; Borgia G; Coppola N
    Hepatol Int; 2019 Jan; 13(1):66-74. PubMed ID: 30523552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From current status to optimization of HCV treatment: Recommendations from an expert panel.
    Craxì A; Perno CF; Viganò M; Ceccherini-Silberstein F; Petta S;
    Dig Liver Dis; 2016 Sep; 48(9):995-1005. PubMed ID: 27388261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.